189 related articles for article (PubMed ID: 34480360)
1. Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population-based study.
Rozema J; van Roon EN; Kibbelaar RE; Veeger NJGM; Slim CL; de Wit H; Hoogendoorn M;
Transfusion; 2021 Oct; 61(10):2877-2884. PubMed ID: 34480360
[TBL] [Abstract][Full Text] [Related]
2. Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).
Jouzier C; Cherait A; Cony-Makhoul P; Hamel JF; Veloso M; Thepot S; Cluzeau T; Stamatoullas A; Garnier A; Guerci-Bresler A; Dimicoli-Salazar S; Pica GM; Cheze S; Santana C; Chermat F; Fenaux P; Park S
Transfusion; 2022 May; 62(5):961-973. PubMed ID: 35452143
[TBL] [Abstract][Full Text] [Related]
3. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
5. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
6. Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.
Rozema J; Hoogendoorn M; Kibbelaar R; van den Berg E; Veeger N; van Roon E
Blood Adv; 2021 Mar; 5(5):1344-1351. PubMed ID: 33656535
[TBL] [Abstract][Full Text] [Related]
7. A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study.
Rozema J; Slim CL; Veeger NJGM; Kibbelaar RE; de Wit H; van Roon EN; Hoogendoorn M
Blood Transfus; 2022 Jan; 20(1):18-26. PubMed ID: 33370223
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
Zeidan AM; Gore SD; McNally DL; Baer MR; Hendrick F; Mahmoud D; Davidoff AJ
Cancer; 2013 Nov; 119(21):3870-8. PubMed ID: 23922173
[TBL] [Abstract][Full Text] [Related]
9. Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes.
DeZern AE; Binder G; Rizvi S; Corvino FA; Arikian SR; Surinach A; Lee J; Smith BD
Leuk Lymphoma; 2017 Nov; 58(11):2649-2656. PubMed ID: 28482722
[TBL] [Abstract][Full Text] [Related]
10. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
11. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
12. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.
Dinmohamed AG; Visser O; van Norden Y; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Eur J Cancer; 2014 Mar; 50(5):1004-12. PubMed ID: 24388662
[TBL] [Abstract][Full Text] [Related]
13. Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes.
King D; Schmidt R; Lesser M; Houk A; Salkeld E; Cogle CR
Leuk Res; 2020 Sep; 96():106425. PubMed ID: 32702549
[TBL] [Abstract][Full Text] [Related]
14. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008.
McQuilten ZK; Polizzotto MN; Wood EM; Sundararajan V
Transfusion; 2013 Aug; 53(8):1714-21. PubMed ID: 23305556
[TBL] [Abstract][Full Text] [Related]
16. Physicians' experience in blood supply shortages and the top factors that impact the clinical, economic, and humanistic outcomes of patients with myelodysplastic syndromes in 5 European countries.
Gupta S; Kulasekararaj AG; Costantino H; Grisolano J; Tang J; Jones S; Tang D
Curr Med Res Opin; 2023 Feb; 39(2):239-247. PubMed ID: 36453466
[TBL] [Abstract][Full Text] [Related]
17. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications.
Gupta P; LeRoy SC; Luikart SD; Bateman A; Morrison VA
Leuk Res; 1999 Oct; 23(10):953-9. PubMed ID: 10573142
[TBL] [Abstract][Full Text] [Related]
18. Red blood cell transfusion in myelodysplastic syndromes: A systematic review.
Kaka S; Jahangirnia A; Beauregard N; Davis A; Tinmouth A; Chin-Yee N
Transfus Med; 2022 Feb; 32(1):3-23. PubMed ID: 34927286
[TBL] [Abstract][Full Text] [Related]
19. Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes.
Ryblom H; Hast R; Hellström-Lindberg E; Winterling J; Johansson E
Eur J Oncol Nurs; 2015 Apr; 19(2):99-106. PubMed ID: 25488465
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
